US 12,186,387 B2
Coronavirus vaccine
Alexander Muik, Seeheim-Jugenheim (DE); Asaf Poran, Stoneham, MA (US); Kena Anne Swanson, Pearl River, NY (US); Qi Yang, Orangeburg, NY (US); Hui Cai, Ridgewood, NJ (US); and Ugur Sahin, Mainz (DE)
Assigned to BioNTech SE, Mainz (DE)
Filed by BioNTech SE, Mainz (DE)
Filed on Nov. 29, 2022, as Appl. No. 18/071,499.
Claims priority of provisional application 63/425,290, filed on Nov. 14, 2022.
Claims priority of provisional application 63/422,404, filed on Nov. 3, 2022.
Claims priority of provisional application 63/417,680, filed on Oct. 19, 2022.
Claims priority of provisional application 63/402,444, filed on Aug. 30, 2022.
Claims priority of provisional application 63/394,571, filed on Aug. 2, 2022.
Claims priority of provisional application 63/358,522, filed on Jul. 5, 2022.
Claims priority of provisional application 63/357,628, filed on Jun. 30, 2022.
Claims priority of provisional application 63/355,648, filed on Jun. 26, 2022.
Claims priority of provisional application 63/355,597, filed on Jun. 25, 2022.
Claims priority of provisional application 63/342,614, filed on May 16, 2022.
Claims priority of provisional application 63/324,586, filed on Mar. 28, 2022.
Claims priority of provisional application 63/302,997, filed on Jan. 25, 2022.
Claims priority of provisional application 63/291,347, filed on Dec. 17, 2021.
Claims priority of provisional application 63/287,486, filed on Dec. 8, 2021.
Claims priority of provisional application 63/283,976, filed on Nov. 29, 2021.
Prior Publication US 2023/0338512 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/215 (2006.01); A61K 9/127 (2006.01); A61K 39/145 (2006.01); A61K 45/06 (2006.01); A61K 47/26 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/215 (2013.01) [A61K 9/1272 (2013.01); A61K 39/145 (2013.01); A61K 45/06 (2013.01); A61K 47/26 (2013.01); C12N 15/86 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55555 (2013.01); C12N 2310/335 (2013.01); C12N 2760/16022 (2013.01); C12N 2760/16034 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01); C12N 2770/20043 (2013.01); C12N 2770/20071 (2013.01)] 28 Claims
 
1. A composition or medical preparation comprising an RNA comprising a nucleotide sequence encoding a SARS-COV-2 Spike(S) protein, wherein the SARS-COV-2 S protein comprises:
(a) at least 10 of the following mutations as compared to SEQ ID NO: 1: A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, and L981F;
(b) an amino acid sequence that is at least 97% identical to SEQ ID NO: 49, or to an immunogenic fragment thereof;
wherein the RNA optionally comprises a modified uridine in place of one or more uridines.